CEOs departing Legend, Sarepta

CEOs are departing from a pair of U.S. mid-cap biotechs, with Doug Ingram retiring from Sarepta and Ying Huang abruptly stepping down from Legend’s C-suite and board. 

Investors were caught off guard by Huang’s departure, with shares of cross-border CAR T company  Legend Biotech Corp. (NASDAQ:LEGN) falling 13% to $19.27 on Monday, a loss of $570 million in market cap. Alan Bash, president of the company’s Carvykti business unit, has been named interim CEO while Legend’s board seeks a permanent successor. ...